This is a phase 1b randomized, double-blind, placebo-controlled study in adult subjects with Coronavirus Disease 2019 (COVID-19). This clinical trial will evaluate the preliminary safety and efficacy of BM-Allo.MSC vs placebo in treating subjects with severe disease requiring ventilator support during COVID 19 infection.
Biological: BM-Allo.MSC
BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.
Biological: Placebo
plasmalyte and human albumin
Inclusion Criteria:
1. Age ≥ 18 years old.
2. Able to understand and provide a signed informed consent that fulfills the relevant
Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines. For
subjects that are intubated and/or sedated, or otherwise unable to provide consent,
prospective consent from a legally-authorized representative is required. The subject
or his/her legally authorized representative must be able to provide consent.
3. Has laboratory-confirmed positive novel coronavirus (SARS-CoV-2) test, as determined
by polymerase chain reaction (PCR), or other commercial or public health assay in any
specimen < 72 hours prior to enrollment, or meets the criteria to guide the evaluation
and testing of patients under investigation (PUI) for COVID-19
(https://emergency.cdc.gov/han/2020/HAN00428.asp).
4. Requiring mechanical ventilatory support with moderate to severe Acute Respiratory
Distress Syndrome (ARDS) as determined by the Berlin criteria:
1. Bilateral opacities present on a chest radiograph or computed tomographic (CT)
scan. These opacities are not fully explained by pleural effusions, lobar
collapse, lung collapse, or pulmonary nodules.
2. Origin of Edema: Respiratory failure not fully explained by cardiac failure or
fluid overload.
3. Oxygenation: Moderate to severe impairment of oxygenation must be present, as
defined by the ratio of arterial oxygen tension to fraction of inspired oxygen
(PaO2/FiO2). The severity of the hypoxemia defines the severity of the ARDS:
- Moderate: PaO2/FiO2 >100 mmHg and ≤ 200 mmHg, on ventilator settings that
include PEEP ≥ 5 cm H2O
- Severe: PaO2/FiO2 ≤100 mmHg on ventilator settings that include PEEP ≥5 cm
H2O Subjects receiving extracorporeal membrane oxygenation (ECMO) will not
be enrolled in this study.
5. High-sensitivity C-reactive Protein (hs-CRP) serum level > 4.0 mg/dL
6. Acute Physiology and Chronic Health Evaluation (APACHE IV) score > 5
7. Agrees to the collection of nasopharyngeal (NP) swabs and venous blood per protocol.
8. Ability to attend required study visits and return for adequate follow-up, as required
by this protocol.
9. Agreement to practice effective contraception for female subjects of child-bearing
potential and non-sterile males. Female subjects of child-bearing potential must agree
to use effective contraception while on study and for at least 1 month after the last
dose of BM-Allo.MSC. Non-sterile male subjects must agree to use a condom while on
study and for up to 1 month after the dose of BM-Allo.MSC. Effective contraception
includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier
methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs),
oral contraceptives, and abstinence.
Exclusion Criteria:
1. Known hypersensitivity to any component of the study medication(s).
2. Signs of multisystem organ failure. Liver function tests (LFTs) > 5x normal.
3. Intubated > 72 continuous hours.
4. Assessed by the Investigator to be unable or unwilling to comply with the requirements
of the protocol.
5. Pregnant and nursing women. A negative serum pregnancy test during screening (within
72 hours prior to the first dose) must be documented before MSCs are administered to a
female subject of child-bearing potential.
St. Francis Medical Center
Lynwood, California, United States